Skip to main content
Clinical Trials/NCT02275637
NCT02275637
Recruiting
N/A

Arrhythmias Detection in a Real World Population: the RHYTHM DETECT Registry

Fondazione IRCCS Policlinico San Matteo di Pavia12 sites in 1 country10,000 target enrollmentSeptember 1, 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Appropriate and Inappropriate Shock Therapy With ICD
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Enrollment
10000
Locations
12
Primary Endpoint
Patients with ICD therapy (shock)
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The study is a prospective multicenter registry. Consecutive patients with indications of implant / replacement or upgrade of implantable cardioverter defibrillator (ICD) will be enrolled.

The primary objective of the study is to determine the predictors of appropriate anti-tachycardia therapy (with shock) in a non-selected population of patients implanted with an ICD.

Secondary objectives of the study are:

  • the incidence of anti-tachycardia therapies;
  • the predictors of inappropriate therapy and onset of arrhythmia burden;
  • the adherence to the current guidelines in the Italian clinical practice;
  • the predictors of heart failure (HF) onset and response to cardiac resynchronization therapy (CRT).
Registry
clinicaltrials.gov
Start Date
September 1, 2014
End Date
December 1, 2028
Last Updated
9 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Responsible Party
Principal Investigator
Principal Investigator

Maurizio Eugenio Landolina

EP and Pacing Laboratory Director

Fondazione IRCCS Policlinico San Matteo di Pavia

Eligibility Criteria

Inclusion Criteria

  • Patient implanted with a Subcutaneous (S)- Ventricular Chamber (VR)- Dual Chamber (DR) - or Cardiac Resynchronization Therapy (CRT) Defibrillator (this study will utilize all the market released CRT-D or VR/DR-ICD systems and leads)
  • Patient is willing and able to sign an authorization to use and disclose health information or an Informed Consent
  • Patient must be able to attend all required follow-up visits at the study center for at least 12 months

Exclusion Criteria

  • Patient is participating in another clinical study that may have an impact on the study endpoints
  • Women who are pregnant or plan to become pregnant

Outcomes

Primary Outcomes

Patients with ICD therapy (shock)

Time Frame: 24 months

Clinical or instrumental parameters that could predict the appropriate ICD therapies

Secondary Outcomes

  • Patients with inappropriate shock therapy(24 months)
  • Time to first ICD therapy(24 months)
  • Predictors of onset and Atrial Fibrillation (AF) burden(24 months)
  • Incidence of ICD therapies(24 months)

Study Sites (12)

Loading locations...

Similar Trials